fluoxetine has been researched along with Refractory Depression in 15 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " There were no significant differences between patients treated with OFC and fluoxetine in extrapyramidal symptoms or serious adverse events." | 2.79 | Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. ( Brunner, E; Landry, J; Osuntokun, O; Thase, ME; Tohen, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (93.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Pardo, JV | 1 |
| Sheikh, SA | 1 |
| Schwindt, G | 1 |
| Lee, JT | 1 |
| Adson, DE | 1 |
| Rittberg, B | 1 |
| Abuzzahab, FS | 1 |
| Strawn, JR | 1 |
| Mills, JA | 1 |
| Croarkin, PE | 1 |
| Lee, CW | 1 |
| Chen, YJ | 1 |
| Wu, HF | 1 |
| Chung, YJ | 1 |
| Lee, YC | 1 |
| Li, CT | 1 |
| Lin, HC | 1 |
| Kin, K | 1 |
| Yasuhara, T | 1 |
| Kawauchi, S | 1 |
| Kameda, M | 1 |
| Hosomoto, K | 1 |
| Tomita, Y | 1 |
| Umakoshi, M | 1 |
| Kuwahara, K | 1 |
| Kin, I | 1 |
| Kidani, N | 1 |
| Morimoto, J | 1 |
| Sasaki, T | 1 |
| Date, I | 1 |
| Hilton, RC | 1 |
| Rengasamy, M | 2 |
| Mansoor, B | 2 |
| He, J | 2 |
| Mayes, T | 1 |
| Emslie, GJ | 2 |
| Porta, G | 2 |
| Clarke, GN | 1 |
| Wagner, KD | 2 |
| Birmaher, B | 2 |
| Keller, MB | 1 |
| Ryan, N | 2 |
| Shamseddeen, W | 2 |
| Asarnow, JR | 1 |
| Brent, DA | 1 |
| Hilton, R | 1 |
| Spirito, A | 1 |
| Mayes, TL | 1 |
| Clarke, G | 1 |
| Brent, D | 1 |
| Brunner, E | 1 |
| Tohen, M | 1 |
| Osuntokun, O | 1 |
| Landry, J | 1 |
| Thase, ME | 1 |
| Vijaya Kumar, K | 1 |
| Rudra, A | 1 |
| Sreedhara, MV | 1 |
| Siva Subramani, T | 1 |
| Prasad, DS | 1 |
| Das, ML | 1 |
| Murugesan, S | 1 |
| Yadav, R | 1 |
| Trivedi, RK | 1 |
| Louis, JV | 1 |
| Li, YW | 1 |
| Bristow, LJ | 1 |
| Naidu, PS | 1 |
| Vikramadithyan, RK | 1 |
| Guo, M | 1 |
| Lu, XY | 1 |
| Ford, N | 1 |
| Ludbrook, G | 1 |
| Galletly, C | 1 |
| Jha, S | 1 |
| Kumar, P | 1 |
| Kumar, R | 1 |
| Das, A | 1 |
| Breitfeld, J | 1 |
| Scholl, C | 1 |
| Steffens, M | 1 |
| Laje, G | 1 |
| Stingl, JC | 1 |
| Houston, JP | 1 |
| Lau, K | 1 |
| Aris, V | 1 |
| Liu, W | 1 |
| Fijal, BA | 1 |
| Heinloth, AN | 1 |
| Perlis, RH | 1 |
| Sukoff Rizzo, SJ | 1 |
| Neal, SJ | 1 |
| Hughes, ZA | 1 |
| Beyna, M | 1 |
| Rosenzweig-Lipson, S | 1 |
| Moss, SJ | 1 |
| Brandon, NJ | 1 |
| Dournes, C | 1 |
| Beeské, S | 1 |
| Belzung, C | 1 |
| Griebel, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)[NCT00018902] | Phase 2/Phase 3 | 334 participants (Actual) | Interventional | 2001-01-31 | Completed | ||
| The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features[NCT00035321] | Phase 3 | 600 participants | Interventional | 2002-04-30 | Completed | ||
| Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder: An Open-Label Trial[NCT02660528] | Phase 2 | 3 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to Study staff change.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for fluoxetine and Refractory Depression
| Article | Year |
|---|---|
Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.
Topics: Adolescent; Anxiety; Attention Deficit and Disruptive Behavior Disorders; Behavioral Symptoms; Cital | 2013 |
The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Body Mass Index; Child; Citalopram; Cyclohexan | 2013 |
Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Benzodiazepines; Depressive Disorder, Major; Depressive Disorder, Trea | 2014 |
Association of common variations in the norepinephrine transporter gene with response to olanzapine-fluoxetine combination versus continued-fluoxetine treatment in patients with treatment-resistant depression: a candidate gene analysis.
Topics: Antidepressive Agents, Second-Generation; Benzodiazepines; Depressive Disorder, Treatment-Resistant; | 2012 |
11 other studies available for fluoxetine and Refractory Depression
| Article | Year |
|---|---|
A preliminary study of resting brain metabolism in treatment-resistant depression before and after treatment with olanzapine-fluoxetine combination.
Topics: Adult; Amygdala; Benzodiazepines; Brain; Depressive Disorder, Treatment-Resistant; Drug Combinations | 2020 |
Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
Topics: Adolescent; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Fluoxe | 2019 |
Ketamine ameliorates severe traumatic event-induced antidepressant-resistant depression in a rat model through ERK activation.
Topics: Amygdala; Animals; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Disease Models, | 2019 |
Lithium counteracts depressive behavior and augments the treatment effect of selective serotonin reuptake inhibitor in treatment-resistant depressed rats.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Disease Models | 2019 |
Bacillus Calmette-Guérin vaccine induces a selective serotonin reuptake inhibitor (SSRI)-resistant depression like phenotype in mice.
Topics: Animals; BCG Vaccine; Behavior, Animal; Brain; Citalopram; Depressive Disorder, Treatment-Resistant; | 2014 |
Leptin receptor deficiency confers resistance to behavioral effects of fluoxetine and desipramine via separable substrates.
Topics: Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Depressive Disorder, Treatment-Resistant; D | 2014 |
Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; De | 2015 |
Effectiveness of add-on l-methylfolate therapy in a complex psychiatric illness with MTHFR C677 T genetic polymorphism.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disor | 2016 |
Gene expression and proliferation biomarkers for antidepressant treatment resistance.
Topics: Adult; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B; Biomarkers; Cell Line; | 2017 |
Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes.
Topics: Analysis of Variance; Animals; Central Nervous System; Cytokine Receptor gp130; Depression; Depressi | 2012 |
Deep brain stimulation in treatment-resistant depression in mice: comparison with the CRF1 antagonist, SSR125543.
Topics: Aggression; Animals; Antidepressive Agents; Behavior, Animal; Brain; Deep Brain Stimulation; Depress | 2013 |